Y-mAbs Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview

Y-mAbs Therapeutics

08/08/2025 16:52

Y-mAbs Therapeutics Inc YMAB.OQ YMAB.O is expected to  show a rise in quarterly revenue when it reports  results on August 8 for the period ending September 30 2025

The Princeton New Jersey-based  company is expected to report a 13.8% increase in revenue to $21.013 million from $18.46 million a year ago, according to the mean estimate from 8 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Y-mAbs Therapeutics Inc is for a loss of 26 cents per share.

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 10 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts had fallen by about 7.3% in the last three months. ​

Wall Street's median 12-month price target for Y-mAbs Therapeutics Inc is $8.60, about 0.9% above its last closing price of $8.52

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Jun. 30 2025
-0.26
-0.27
-0.07
Beat
73.6
Mar. 31 2025
-0.21
-0.21
-0.12
Beat
43.3
Dec. 31 2024
-0.11
-0.12
-0.15
Missed
-21.2​
Sep. 30 2024
-0.16
-0.16
-0.16
Met
-1.6
​​Jun. 30 2024
-0.13
-0.13
-0.21
Missed
-59.8
Mar. 31 2024
-0.14
-0.14
-0.15
Missed
-10.5​
Dec. 31 2023
-0.20
-0.20
-0.02
Beat
90.1
Sep. 30 2023
-0.18
-0.19
-0.18
Beat
3.7

This summary was machine generated August 8 at 15:52 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)